Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EU-WHO Strategic Dialogue on Health

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

- PMLiVE

J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma

The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse

- PMLiVE

Astellas announces EC approval of Xtandi for expanded prostate cancer use

Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

- PMLiVE

World Health Organization prequalifies simplified oral cholera vaccine Euvichol-S

The acute diarrhoeal illness was reported to affect around 473,000 people in 2022

EU flag

European Parliament approves pharma reform compromise for equal access to new medicines

The new proposal will be finalised after the EU elections take place in June 2024

- PMLiVE

World Health Organization launches AI-powered digital health assistant for public health

SARAH has been launched in alignment with World Health Day’s theme, ‘My Health, My Right’

- PMLiVE

Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links